These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 15927253

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A, Robak T, Pluta A, Zwolińska M, Wawrzyniak E, Wierzbowska A, Skotnicki A, Jakubas B, Hołowiecki J, Nowak K, Kuliczkowski K, Mazur G, Haus O, Dmoszyńska A, Adamczyk-Cioch M, Jedrzejczak WW, Paluszewska M, Konopka L, Pałynyczko G.
    Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
    [Abstract] [Full Text] [Related]

  • 6. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J, Huang X, Jiang B, Qin Y, Bao L, Jiang H, Chen H, Jia J, Yang S, Jiang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
    Pompetti F, Spadano A, Sau A, Mennucci A, Russo R, Catinella V, Franchi PG, Calabrese G, Palka G, Fioritoni G, Iacone A.
    Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L, Luppi M, Riva G, Marasca R, Martinelli S, Torelli G.
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 16. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 17. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
    J Clin Oncol; 2006 Jan 20; 24(3):454-9. PubMed ID: 16421422
    [Abstract] [Full Text] [Related]

  • 18. [Prognostic significance of Ph-positive acute lymphoblastic leukemia].
    Zhou L, Hu J, Chen J, Du S, Wang A, You J, Wu W, Shen Z, Li J.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb 20; 35(2):109-13. PubMed ID: 24606650
    [Abstract] [Full Text] [Related]

  • 19. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
    Colombat M, Fort MP, Chollet C, Marit G, Roche C, Preudhomme C, Reiffers J, Praloran V, Mahon FX.
    Haematologica; 2006 Feb 20; 91(2):162-8. PubMed ID: 16461299
    [Abstract] [Full Text] [Related]

  • 20. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
    Hess G, Meyer RG, Schuch B, Bechthold K, El-Kholy I, Huber C.
    Am J Hematol; 2008 Mar 20; 83(3):178-84. PubMed ID: 17876770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.